-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Roodehaan Solar PV Park
Roodehaan Solar PV Park is a solar PV project located in Groningen, Netherlands. The project is owned by Sunrock Investments BV and was developed by Hanergy Thin Film Power Group Ltd; Solar Energy Works BV. The project came online in 2019. Empower your strategies with our Roodehaan Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day...
-
Product Insights
Sunrock Tilburg Solar PV Plant
Sunrock Tilburg solar PV Plant is a 10.582MW solar PV power project located in North Brabant, Netherlands. It is being developed by Sunrock Assets XIX BV. The project is currently in the permitting stage. The project is owned by Sunrock Assets XIX BV. Sunrock Tilburg solar PV Plant profile includes core details such as plant name, technology, capacity, status, plant proponents (owners, developers etc.), owner stakes etc as well as key operational data including generation, year online, decommissioning year, capital...
-
Product Insights
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections, and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain, and breathing problems. Treatment includes chemotherapy, transfusions, transplant, and medications. The ALL pipeline drugs market research report provides comprehensive information on the therapeutics under...